C. Ola Landgren, M.D. (IMAGE)

University of Miami Miller School of Medicine

C. Ola Landgren, M.D.

Caption

“Now we have chemotherapy-free immunotherapy options for patients whose myeloma has relapsed for the first time,” said C. Ola Landgren, M.D., chief of the Sylvester Myeloma Institute. “We are seeing very deep responses and long clinical benefit from these therapies. This is part of a much bigger transformation happening in myeloma care.”

Credit

Sylvester Comprehensive Cancer Center

Usage Restrictions

Use with attribution

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.